Anna Spathis1, Kate Fife2, Fiona Blackhall2, Susan Dutton2, Ronja Bahadori2, Rose Wharton2, Mary O'Brien2, Patrick Stone2, Tim Benepal2, Nick Bates2, Bee Wee2. 1. Anna Spathis and Kate Fife, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Fiona Blackhall, The Christie NHS Foundation Trust and University of Manchester, Manchester; Susan Dutton, Ronja Bahadori, Rose Wharton, and Bee Wee, University of Oxford; Bee Wee, Sir Michael Sobell House, Oxford; Mary O'Brien, Royal Marsden Hospital; Patrick Stone, St George's University of London; Tim Benepal, St George's Hospital NHS Trust, London; and Nick Bates, Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom. aspathis@doctors.org.uk. 2. Anna Spathis and Kate Fife, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Fiona Blackhall, The Christie NHS Foundation Trust and University of Manchester, Manchester; Susan Dutton, Ronja Bahadori, Rose Wharton, and Bee Wee, University of Oxford; Bee Wee, Sir Michael Sobell House, Oxford; Mary O'Brien, Royal Marsden Hospital; Patrick Stone, St George's University of London; Tim Benepal, St George's Hospital NHS Trust, London; and Nick Bates, Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom.
Abstract
PURPOSE: Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo. The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue score from baseline to 28 days, adjusted for baseline fatigue and performance status. Secondary outcomes included safety and patient-reported measures of depression, daytime sleepiness, and quality of life. RESULTS: A total of 208 patients were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis. FACIT-Fatigue scores improved from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95% CI, 2.54 to 7.65), but there was no difference between treatments (0.20; 95% CI, -3.56 to 3.97). There was also no difference between treatments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that the intervention was not helpful. CONCLUSION: Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting. Its use was associated with a clinically significant placebo effect.
PURPOSE: Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo. The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue score from baseline to 28 days, adjusted for baseline fatigue and performance status. Secondary outcomes included safety and patient-reported measures of depression, daytime sleepiness, and quality of life. RESULTS: A total of 208 patients were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis. FACIT-Fatigue scores improved from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95% CI, 2.54 to 7.65), but there was no difference between treatments (0.20; 95% CI, -3.56 to 3.97). There was also no difference between treatments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that the intervention was not helpful. CONCLUSION: Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting. Its use was associated with a clinically significant placebo effect.
Authors: Eudocia Q Lee; Alona Muzikansky; Jan Drappatz; Santosh Kesari; Eric T Wong; Camilo E Fadul; David A Reardon; Andrew D Norden; Lakshmi Nayak; Mikael L Rinne; Brian M Alexander; Nils D Arvold; Lisa Doherty; Jennifer Stefanik; Debra LaFrankie; Sandra F Ruland; Julee Pulverenti; Katrina H Smith; Sarah C Gaffey; Samantha Hammond; Patrick Y Wen Journal: Neuro Oncol Date: 2016-02-21 Impact factor: 12.300
Authors: Anna Spathis; Sara Booth; Sarah Grove; Helen Hatcher; Isla Kuhn; Stephen Barclay Journal: J Adolesc Young Adult Oncol Date: 2015-03 Impact factor: 2.223
Authors: Anita R Peoples; Sheila N Garland; Michael L Perlis; Josée Savard; Charles E Heckler; Charles S Kamen; Julie L Ryan; Karen M Mustian; Michelle C Janelsins; Luke J Peppone; Gary R Morrow; Joseph A Roscoe Journal: J Cancer Surviv Date: 2017-01-19 Impact factor: 4.442
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908
Authors: Claire C Conley; Charles S Kamen; Charles E Heckler; Michelle C Janelsins; Gary R Morrow; Luke J Peppone; Anthony J Scalzo; Howard Gross; Shaker Dakhil; Karen M Mustian; Oxana G Palesh Journal: J Clin Psychopharmacol Date: 2016-02 Impact factor: 3.153